Litcius/Paper detail

RETRACTED: Co-delivery of paclitaxel and curcumin loaded solid lipid nanoparticles for improved targeting of lung cancer: In vitro and in vivo investigation

Mao Li, Gang Fang, Fatima Zahid, Raheela Saleem, Ghazala Ishrat, Zakir Ali, Muhammad Naeem, Fakhar ud Din

2024Heliyon43 citationsDOIOpen Access PDF

Abstract

tumor investigation of PAC-CUR-SLNs exhibited 12-fold reduced tumor volume and almost no change in body weight of BALB/c mice, when compared with the experimental groups including control group. The inhibition of tumor rate on day 28 was 82.7 % in the PAC-CUR-SLNs group, which was significantly higher than the pure drugs and monotherapies. It can be concluded that, encapsulating the co-loaded antitumor drugs like PAC-CUR in SLNs may help in improved targeting of the tumor with enhanced anticancer effect.

Topics & Concepts

CurcuminSolid lipid nanoparticlePaclitaxelIn vivoLung cancerPharmacologyIn vitroCancerChemistryMedicineNanotechnologyMaterials scienceOncologyInternal medicineBiochemistryBiologyDrugBiotechnologyCurcumin's Biomedical ApplicationsAdvancements in Transdermal Drug DeliveryNanoparticle-Based Drug Delivery
RETRACTED: Co-delivery of paclitaxel and curcumin loaded solid lipid nanoparticles for improved targeting of lung cancer: In vitro and in vivo investigation | Litcius